[Biojava-dev] IBC LIFE SCIENCES 10TH ANNUAL ANTIBODY PRODUCTION & DOWNSTREAM PROCESSING EVENT

[support at biotaq.com]

KEITH WEBBER, Ph.D., OF CBER, FDA TO PRESENT AT
IBC LIFE SCIENCES 10TH ANNUAL
ANTIBODY PRODUCTION & DOWNSTREAM PROCESSING EVENT

IBC's Antibody Production & Downstream Processing is celebrating 10 years
of providing superior content and networking to the Biopharmaceutical
industry. It has announced that Keith Webber, of CBER and FDA will present
the Keynote Address at this meeting to be held on March 5-7, 2003 at the
Hilton La Jolla Torrey Pines in La Jolla, CA.  Co-Located with Process
Validation for Biologicals and Antibody Partnering & Collaboration both
held March 3-4, 2003, this 10 year celebration will provide the top notch
presenters a venue to discuss the essentials for producing therapeutic
antibodies and learn how to maximize production efficiency. The meeting is
expected to surpass its previous year's attendance of over 500 attendees
and over 40 exhibit booths.

Keith Webber, Director, Division of Monoclonal Antibodies, Office of
Therapeutic Research and Review, CBER, FDA will present the Keynote
Address on FDA Regulation of Biologics Produced in Bioengineered Plants.
Dr. Webber is Chair of the FDA/USDA Interagency Working Group that has
recently published a draft Guidance for Industry on drugs, biologics, and
medical devices derived from bioengineered plants for use in humans and
animals.

The content of the meeting focuses primarily on the most relevant aspects
of antibody manufacturing. Some of the highlights will include:
·	Thomas Harnett revealing the design considerations for start-up and
operation of Centocor's new Malvern, PA Facility
·	Greg Blank of Genentech discussing the criteria for what makes a good
manufacturing process within the context of high volume production
·	Brian Hubbard of Amgen divulging the changes implemented to the approved
commercial process for manufacture of Enbrel®
·	Lynn Conley of IDEC Pharmaceuticals detailing the challenges encountered
with developing the purification and conjugation process for Zevalin
·	Reed Harris of Genentech delivering new data about the impact of c
glycans on the clearance of XolairTM

For more information on attending Antibody Production & Downstream
Processing in La Jolla, March 5-7, 2003, visit
http://www.lifesciencesinfo.com/antibodyprod
Or call 508-616-5550, X1004
********************************************************
This segmented email list tends to serve the people who are
interested in news and product info in Proteomics sector. To edit
or change your interest category selections or unsubscribe,simply
reply to this email.

To distribute your releases to this list, contact sales at biotaq.com.

BIOTAQ.COM's email news service is focused exclusively on biotech
industry. Welcome to join BIOTAQ.COM at:

http://www.biotaq.com/Joinbiotaq.htm
**************************************************************************
**